Oncologist-led germline genetic testing for uveal melanoma

References

• Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32(4):239–51. doi:10.1016/0039-6257(88)90173-7.
   PubMed Web of Science ®Google Scholar
• Metzelaar-Blok JA, Ter Huurne JA, Hurks HM, Keunen JE, Jager MJ, Gruis NA. Characterization of melanocortin-1 receptor gene variants in uveal melanoma patients. Investig Ophthalmol Vis Sci. 2001;42(9):1951–54.
   Google Scholar
• Young LH, Egan KM, Walsh SM, et al. Familial uveal melanoma. Am J Ophthalmol. Investig Ophthalmol. 1994;117:516–20. doi:10.1016/S0002-9394(14)70014-5
   Google Scholar
• Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250(4988):1684–9. doi:10.1126/science.2270482.
   PubMed Web of Science ®Google Scholar
• Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088–90. doi:10.1126/science.8091231.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48(12):856–9. doi:10.1136/jmedgenet-2011-100156.
   PubMed Web of Science ®Google Scholar
• Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022–5. doi:10.1038/ng.912.
   PubMed Web of Science ®Google Scholar
• Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43(10):1018–21. doi:10.1038/ng.910.
   PubMed Web of Science ®Google Scholar
• Aoude LG, Vajdic CM, Kricker A, Armstrong B, Hayward NK. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. Pigment Cell Melanoma Res. 2013;26(2):278–9. doi:10.1111/pcmr.12046.
   PubMed Web of Science ®Google Scholar
• Gupta MP, Lane AM, DeAngelis MM, Mayne K, Crabtree M, Gragoudas ES, Kim IK. Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmol. 2015;133(8):881–7. doi:10.1001/jamaophthalmol.2015.1119.
   PubMed Web of Science ®Google Scholar
• Repo P, Järvinen RS, Jäntti JE, Markkinen S, Täll M, Raivio V, Turunen JA, Kivelä TT. Population-based analysis of BAP1 germline variations in patients with uveal melanoma. Hum Mol Genet. 2019;28(14):2415–26. doi:10.1093/hmg/ddz076.
   PubMed Web of Science ®Google Scholar
• Turunen JA, Markkinen S, Wilska R, Saarinen S, Raivio V, Täll M, Lehesjoki AE, Kivelä TT. BAP1 germline mutations in Finnish patients with uveal melanoma. Ophthalmology. 2016;123(5):1112–7. doi:10.1016/j.ophtha.2016.01.008.
   PubMed Web of Science ®Google Scholar
• Rai K, Pilarski R, Boru G, Rehman M, Saqr AH, Massengill JB, Singh A, Marino MJ, Davidorf FH, Cebulla CM, et al. Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes Cancer. 2017;56(2):168–74. doi:10.1002/gcc.22424.
   PubMed Web of Science ®Google Scholar
• Cruz C, Teule A, Caminal JM, Blanco I, Piulats JM. Uveal melanoma and BRCA1/BRCA2 genes: a relationship that needs further investigation. J Clin Oncol. 2011;29(34):e827–9. doi:10.1200/JCO.2011.37.8828.
   PubMed Web of Science ®Google Scholar
• Johansson PA, Stark A, Palmer JM, Bigby K, Brooks K, Rolfe O, Pritchard AL, Whitehead K, Warrier S, Glasson W, et al. Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab. Immunogenetics. 2019;71(5–6):433–6. doi:10.1007/s00251-019-01108-x.
   PubMed Web of Science ®Google Scholar
• Nathan V, Palmer JM, Johansson PA, Hamilton HR, Warrier SK, Glasson W, McGrath LA, Kahl V, Vasireddy RS, Pickett HA, et al. Loss-of-function variants in POT1 predispose to uveal melanoma. J Med Genet. 2021;58(4):234–6. doi:10.1136/jmedgenet-2020-107098.
   PubMed Web of Science ®Google Scholar
• Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B. CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Genes Chromosomes Cancer. 2003;38(3):265–8. doi:10.1002/gcc.10286.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman MH, Sample KM, Pilarski R, Walsh T, Grosel T, Kinnamon D, Boru G, Massengill JB, Schoenfield L, Kelly B, et al. Whole exome sequencing identifies candidate genes associated with hereditary predisposition to uveal melanoma. Ophthalmology. 2020;127(5):668–78. doi:10.1016/j.ophtha.2019.11.009.
   PubMed Web of Science ®Google Scholar
• Walpole S, Hayward N, Pritchard A, Johansson P. Microsimulation model for evaluating the cost-effectiveness of surveillance in BAP1 pathogenic variant carriers. JCO Clinical Cancer Informatics. 2021;5:143–54. doi:10.1200/CCI.20.00124.
   PubMed Web of Science ®Google Scholar
• Cancer Care Ontario. Recommendation report for Ontario’s clinical genetic services. 2018. https://www.cancercareontario.ca/sites/ccocancercare/files/assets/ClinicalGeneticServicesRecommendationReport.pdf.
   Google Scholar
• Chau C, van Doorn R, van Poppelen NM, van der Stoep N, Mensenkamp AR, Sijmons RH, van Paassen BW, van den Ouweland AMW, Naus NC, et al. Families with BAP1-tumor predisposition syndrome in the Netherlands: path to identification and a proposal for genetic screening guidelines. Cancers. 2019;11(8):1114. doi:10.3390/cancers11081114.
   PubMed Web of Science ®Google Scholar
• Cancer Care Ontario. 2021 hereditary cancer testing eligibility criteria: version 2. 2021. https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/70161.
   Google Scholar
• Hoskovec JM, Bennet RL, Carey ME, DaVanzo JE, Dougherty M, Hahn SE, LeRoy BS, O’Neal S, Richardson JG, Wicklund CA. Projecting the supply and demand for certified genetic counselors: a workforce study. J Genet Couns. 2017;27(1):16–20. doi:10.1007/s10897-017-0158-8.
   PubMed Web of Science ®Google Scholar
• Dragojlovic N, Borle K, Kopac N, Ellis U, Birch P, Adam S, Friedman JM, Nisselle A, Elliott AM, Lynd LD, et al. The composition and capacity of the clinical genetics workforce in high-income countries: a scoping review. Genet Med. 2020;22(9):1437–49. doi:10.1038/s41436-020-0825-2.
   PubMed Web of Science ®Google Scholar
• Costa T, Gillies B, Oh T, Scott J. The Canadian genetic counseling workforce: perspectives from employers and recent graduates. J Genet Couns. 2021;30:406–17. doi:10.1002/jgc4.1326.
   PubMed Web of Science ®Google Scholar
• George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, Cloke V, Slade I, Kemp Z, Gore M, et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep. 2016;6:29506.
   PubMed Web of Science ®Google Scholar
• Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, Van Le L, Ghamande S, González-Santiago S, Bover I, et al. Evaluation of a streamlined oncologist-led BRCA Mutation testing and counseling model for patients with ovarian cancer. J Clin Oncol. 2018;36:1300–7.
   PubMed Web of Science ®Google Scholar
• Richardson M, Min HJ, Hong Q, Compton K, Mung SW, Lohn Z, Nuk J, McCullum M, Portigal-Todd C, Karsan A, et al. Oncology clinic-based hereditary cancer genetic testing in a population-based health care system. Cancers. 2020;12:338.
   PubMed Web of Science ®Google Scholar
• McCuaig JM, Thain E, Malcolmson J, Keshavarzi S, Armel SR, Kim RH. A comparison of patient-reported outcomes following consent for genetic testing using an oncologist- or genetic counselor-mediated model of care. Current Oncol. 2021;28(2):1459–71. doi:10.3390/curroncol28020138.
   PubMed Web of Science ®Google Scholar
• Primiero CA, Finnane A, Yanes T, Peach B, Soyer HP, McInerney-Leo AM. Protocol to evaluate a pilot program to upskill clinicians in providing genetic testing for familial melanoma. PloS One. 2022;17(12):e0275926. doi:10.1371/journal.pone.0275926.
   PubMed Web of Science ®Google Scholar
• Moran A, O’hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer. 2012;11:235–42 doi:10.1007/s10689-011-9506-2.
   PubMed Web of Science ®Google Scholar
• Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res. 2000;60(24):6864–7.
   PubMed Web of Science ®Google Scholar
• Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricalà C, Dalle S, Duval-Modeste AB, Ghiorzo P, et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet. 2013;50(4):264–70. doi:10.1136/jmedgenet-2012-101455.
   PubMed Web of Science ®Google Scholar
• Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fargnoli MC, Ghiorzo P, Bressac-de Paillerets B, Nagore E, Avril MF, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014;46(5):482–6. doi:10.1038/ng.2941.
   PubMed Web of Science ®Google Scholar
• Kanetsky PA, Panossian S, Elder DE, Guerry D, Ming ME, Schuchter L, Rebbeck TR. Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer. 2010;116:2416–28. doi:10.1002/cncr.24994.
   PubMed Web of Science ®Google Scholar
• Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, Fargnoli MC. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer. 2008;122:2753–60. doi:10.1002/ijc.23396.
   PubMed Web of Science ®Google Scholar
• David KL, Best RG, Brenman LM, Bush L, Deignan JL, Flannery D, Hoffman JD, Holm I, Miller DT, O’leary J et al. Patient re-contact after revision of genomic test results: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2019;21(4):769–71. doi:10.1038/s41436-018-0391-z.
   PubMed Web of Science ®Google Scholar
• Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol. 2018;30(2):102–9. doi:10.1016/j.joco.2018.02.005.
   PubMed Web of Science ®Google Scholar
• Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–3. doi:10.1126/science.1194472.
   PubMed Web of Science ®Google Scholar
• Mandelker D, Donoghue M, Talukdar S, Bandlamudi C, Srinivasan P, Vivek M, Jezdic S, Hanson H, Snape K, Kulkarni A, et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO precision medicine working group. Ann of Oncol. 2019;30(8):1221–31. doi:10.1093/annonc/mdz136.
   PubMed Web of Science ®Google Scholar
• Bokkers K, Bleiker EMA, Hoogendam JP, Velthuizen ME, Schreuder HWR, Gerestein CG, Lange JG, Louwers JA, Koudijs MJ, Ausems MGEM, et al. Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing. Hered Cancer Clin Pract. 2022;20:33.
   PubMed Web of Science ®Google Scholar
• Plaskocinska I, Shipman H, Drummond J, Thompson E, Buchanan V, Newcombe B, Hodgkin C, Barter E, Ridley P, Ng R, et al. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. J Med Genet. 2016;53(10):655–61. doi:10.1136/jmedgenet-2016-103902.
   PubMed Web of Science ®Google Scholar
• Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, et al. Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Netw Open. 2019 May 3;2(5):e194428. doi:10.1001/jamanetworkopen.2019.4428.
   PubMed Web of Science ®Google Scholar
• Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N, George A, Krell J. Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: a study of 255 patients and its impact on their management. Sci Rep. 2020;10(1):3390. doi:10.1038/s41598-020-60149-5.
   PubMed Web of Science ®Google Scholar
• Piedimonte S, Power J, Foulkes WD, Weber E, Palma L, Schiavi A, Ambrosio E, Konci R, Gilbert L, Jardon K, et al. BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral. Int J Gynecol Cancer. 2020;30(11):1757–61. doi:10.1136/ijgc-2020-001261.
   PubMed Web of Science ®Google Scholar
• Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7. doi:10.1158/1078-0432.CCR-11-2283.
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature. 2011;480(7375):99–103. doi:10.1038/nature10630.
   PubMed Web of Science ®Google Scholar
• Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, DeAngelis MM, Gragoudas E, Duncan LM, Tsao H, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PloS One. 2012;7(4):e35295. doi:10.1371/journal.pone.0035295.
   PubMed Web of Science ®Google Scholar
• Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89(3):285–94. doi:10.1111/cge.12630.
   PubMed Web of Science ®Google Scholar
• Pilarski R, Carlo MI, Cebulla C, Abdel-Rahman M. BAP1 tumor predisposition syndrome. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington; 1993–2022. 2016 Oct 13 [accessed 2022 Mar 24]. https://www.ncbi.nlm.nih.gov/books/NBK390611/.
   Google Scholar
• Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields JA. American joint committee on cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. Ophthalmology. 2013;120(10):2066–71. doi:10.1016/j.ophtha.2013.03.012.
   PubMed Web of Science ®Google Scholar
• Kanetsky PA, Rebbeck TR, Hummer AJ, Panossian S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Culver HA, et al. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res. 2006;66(18):9330–7. doi:10.1158/0008-5472.CAN-06-1634.
   PubMed Web of Science ®Google Scholar
• Pasquali E, García-Borrón JC, Fargnoli MC, Gandini S, Maisonneuve P, Bagnardi V, Specchia C, Liu F, Kayser M, Nijsten T, et al. MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented caucasians: a pooled-analysis from the M-SKIP projectMC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer. 2015;136(3):618–31. doi:10.1002/ijc.29018.
   PubMed Web of Science ®Google Scholar
• Sculco M, La Vecchia M, Aspesi A, Clavenna MG, Salvo M, Borgonovi G, Pittaro A, Witel G, Napoli F, Listì A, et al. Diagnostics of BAP1-tumor predisposition syndrome by a multitesting approach: a ten-year-long experience. Diagnostics. 2022;12(7):1710. doi:10.3390/diagnostics12071710.
   Web of Science ®Google Scholar
• Slade I, Hanson H, George A, Kohut K, Strydom A, Wordsworth S, Rahman N, MCG Programme, Slade I, Hanson H, et al. A cost analysis of a cancer genetic service model in the UK. J Community Genet. 2016;7(3):185–94. doi:10.1007/s12687-016-0266-4.
   PubMedGoogle Scholar